L2M NSERC - Integrated Microfluidic Electrochemical Assay for Cervical Cancer Detection at Point-of-Care Testing

宫颈癌（CC）是一种可治愈的疾病，但由于缺乏筛查和治疗，在低收入和中等收入国家（LMIC）每年约有311000名妇女死于宫颈癌。CC：如果早期发现，可以成功治疗。然而，获得预防、筛查和治疗的机会有限，导致90%的CC相关死亡。发达国家目前用于CC筛查的技术相对昂贵，同时还需要先进的设备和训练有素的专业人员，而这些在低收入国家都不容易获得。我们已经开发出一种自动化的，具有成本效益的便携式设备，可以筛选女性CC。我们的设备由两个主要模块组成：i）用于样品处理的微流体部分，以及ii）用于目标识别的电化学生物传感器。我们已经在实验室和加标样品中表征了我们设备的准确性。我们相信我们的设备有潜力改变偏远地区的CC检测和筛查。

Cervical Cancer (CC) is a curable disease, yet it kills about 311000 women yearly in low- and middle-income countries (LMIC) due to lack of screening and treatment. CC; if detected early, can successfully be treated. However, limited access to prevention, screening, and treatment contributes to 90% of the CC-associated deaths. Current techniques used for CC screening in developed countries are relatively expensive while also requiring sophisticated equipment and trained professionals, none of which is easily accessible in LMIC. We have developed an automated, cost-effective, and portable device that can screen women for CC. Our device consists of two main modules: i) a microfluidic part for sample processing, and ii) an electrochemical biosensor for target identification. We have characterized the accuracy of our device in the lab and with spiked samples. We believe our device has the potential to transform CC detection and screening at remote locations.